Advertisement
GKOS vs NTRA
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Natera, Inc. (NTRA) Stock Comparison
Key Takeaways
- GKOS reported Q1 2026 revenue of $150.6 million, up 41% year-over-year, beating estimates and prompting a raised full-year guidance to $620-635 million.
- NTRA boasts a larger market cap of approximately $29.6 billion compared to GKOS's $8.2 billion, reflecting broader scale in genetic diagnostics.
- GKOS shares have gained 24% year-to-date, outperforming NTRA's 9.5% YTD return amid recent market activity.
- Both stocks operate in high-growth healthcare subsectors, with GKOS focused on glaucoma therapies and NTRA on cell-free DNA (cfDNA) testing for oncology and women's health.
- Analyst sentiment remains positive for both, with GKOS rated Strong Buy (average price target $136-151) and NTRA Outperform (average $258).
- Recent momentum favors GKOS due to earnings-driven gains, while NTRA awaits Q1 results on May 7.
Introduction
Glaukos Corporation (GKOS) and Natera, Inc. (NTRA) represent innovative players in the healthcare sector, with GKOS advancing ophthalmic medical technologies and NTRA pioneering genetic diagnostics. This stock comparison analyzes their recent performance, growth trajectories, and market positioning amid evolving investor interest in medtech and biotech. Traders seeking exposure to specialized healthcare growth stocks, particularly those with strong revenue momentum and analyst support, may find value in evaluating relative strengths in this dynamic environment.
GKOS Overview and Recent Performance
Glaukos Corporation (GKOS) develops therapies for glaucoma and other eye disorders, including micro-bypass stents like iStent inject and iDose TR, an intracameral implant for intraocular pressure reduction. In recent market activity, GKOS shares surged following robust Q1 2026 results, with net sales reaching a record $150.6 million, up 41% year-over-year and exceeding expectations by 10%. The company raised its full-year 2026 sales guidance, driven by U.S. glaucoma product adoption, particularly iDose TR. Year-to-date gains stand at 24%, reflecting positive sentiment from earnings beats and analyst upgrades, including J.P. Morgan's raised price target. Trading around $117, GKOS benefits from a direct sales model to surgery centers and physicians, though it remains unprofitable with negative EPS.
NTRA Overview and Recent Performance
Natera, Inc. (NTRA) specializes in cell-free DNA testing, offering products like Signatera for molecular residual disease (MRD) monitoring in cancer patients and Panorama for non-invasive prenatal screening. Recent weeks have seen sustained interest, bolstered by William Blair's Outperform initiation and publications validating Signatera in clinical trials. Shares trade near $208, with year-to-date returns of 9.5% and one-year gains of 37%, supported by prior Q4 beats and 35% revenue growth. With a substantial $2.3 billion trailing twelve-month revenue base, NTRA serves labs and clinicians globally via direct sales and partnerships. Analyst targets average $258, though Q1 earnings on May 7 could influence near-term sentiment. Like peers, profitability challenges persist with negative EPS.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots from its library of over 350 bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML signal generation, trend trading, and risk-managed virtual agents, operating on timeframes from 5 minutes to days with features such as take-profit/stop-loss corridors (e.g., 3%/2%). The 25 featured trending bots display impressive stats, including annualized returns ranging from 50% to over 160%, win rates of 50-88%, and profit factors up to 7+, often outperforming the S&P 500 in volatile sectors like semiconductors and small caps. While neither GKOS nor NTRA appears in current lineups, exploring these bots offers traders data-driven insights tailored to market conditions.
Head-to-Head Comparison
GKOS and NTRA both target high-growth healthcare niches but differ in business models: GKOS emphasizes implantable devices for glaucoma via a direct sales force, while NTRA focuses on recurring revenue from diagnostic tests distributed through labs and partnerships. Growth drivers include GKOS's iDose adoption versus NTRA's oncology expansions like Signatera. Recent momentum favors GKOS with 24% YTD gains post-earnings, outpacing NTRA's steadier 9.5%. Risk factors encompass clinical trial dependencies and losses for both, with NTRA's larger scale ($30B market cap) offering diversification but higher valuation multiples. Sector exposure highlights medtech stability for GKOS versus biotech volatility for NTRA, shaping distinct sentiment profiles.
Tickeron AI Verdict
Tickeron's AI models would likely favor GKOS in the current environment, given its superior recent trend consistency, 41% revenue acceleration, guidance upgrade, and relative outperformance versus NTRA. While NTRA shows strong positioning ahead of earnings, GKOS's catalysts suggest higher probabilistic upside for momentum traders.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a StrongBuy and NTRA is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 0 green FA rating(s).
- GKOS’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 6 TA indicator(s) are bullish while NTRA’s TA Score has 5 bullish TA indicator(s).
- GKOS’s TA Score: 6 bullish, 4 bearish.
- NTRA’s TA Score: 5 bullish, 4 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а -6.63% price change this week, while NTRA (@Medical Specialties) price change was +6.63% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.44%. For the same industry, the average monthly price growth was +1.11%, and the average quarterly price growth was -4.24%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.07%. For the same industry, the average monthly price growth was +1.78%, and the average quarterly price growth was -5.78%.
Reported Earning Dates
GKOS is expected to report earnings on Aug 05, 2026.
NTRA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.44% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+2.07% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GKOS | NTRA | GKOS / NTRA | |
| Capitalization | 7.88B | 31.4B | 25% |
| EBITDA | -144M | -220.54M | 65% |
| Gain YTD | 18.811 | -4.046 | -465% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 551M | 2.31B | 24% |
| Total Cash | 277M | 1.08B | 26% |
| Total Debt | 103M | 214M | 48% |
GKOS | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 65 | 43 | |
SMR RATING 1..100 | 95 | 93 | |
PRICE GROWTH RATING 1..100 | 40 | 47 | |
P/E GROWTH RATING 1..100 | 61 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for GKOS (94) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than GKOS’s over the last 12 months.
NTRA's Profit vs Risk Rating (43) in the Biotechnology industry is in the same range as GKOS (65) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
NTRA's SMR Rating (93) in the Biotechnology industry is in the same range as GKOS (95) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
GKOS's Price Growth Rating (40) in the Medical Specialties industry is in the same range as NTRA (47) in the Biotechnology industry. This means that GKOS’s stock grew similarly to NTRA’s over the last 12 months.
GKOS's P/E Growth Rating (61) in the Medical Specialties industry is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that GKOS’s stock grew somewhat faster than NTRA’s over the last 12 months.
| GKOS | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 75% | 1 day ago 82% |
| Advances ODDS (%) | 12 days ago 77% | 1 day ago 80% |
| Declines ODDS (%) | 4 days ago 67% | 10 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 78% | 3 days ago 73% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| INMU | 24.11 | 0.01 | +0.04% |
| iShares Intermediate Muni Income Act ETF | |||
| OOSP | 10.14 | N/A | N/A |
| Obra Opportunistic Structured Prdcts ETF | |||
| AOTG | 59.77 | -0.13 | -0.21% |
| AOT Growth and Innovation ETF | |||
| IVLU | 41.77 | -0.66 | -1.56% |
| iShares Edge MSCI Intl Value Factor ETF | |||
| CIFU | 27.45 | -3.59 | -11.57% |
| T-REX 2X LONG CIFR DAILY TARGET ETF | |||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +2.20% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.39% | ||
| GH - NTRA | 48% Loosely correlated | +0.20% | ||
| VCYT - NTRA | 47% Loosely correlated | -1.04% | ||
| GKOS - NTRA | 47% Loosely correlated | -0.83% | ||
| SMTI - NTRA | 45% Loosely correlated | -0.63% | ||
More | ||||